Abstracts Archive - Page 1649 of 2425 - ACR Meeting Abstracts

Abstract Number: 2654 • 2015 ACR/ARHP Annual Meeting
The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry
Dimitrios A. Pappas^1,2, Robert J. Holt³, Ying Shan⁴, Jeffrey D. Kent⁵, John T. Nguyen⁴, Joel M. Kremer⁶ and Jeffrey D. Greenberg^2,7, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³University of Illinois - Chicago, Chicago, IL, ⁴Corrona, LLC., Southborough, MA, ⁵Horizon Pharma USA, Inc., Deerfield, IL, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The ACR/EULAR Boolean definition of remission is expected to be used as an outcome measure in randomized clinical trials for rheumatoid arthritis (RA). Boolean…
Abstract Number: 2655 • 2015 ACR/ARHP Annual Meeting
Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare
VP Bykerk^1,2, Clifton O. Bingham III³, Ernest H. Choy⁴, Daming Lin², Rieke Alten⁵, Robin Christensen⁶, Daniel E. Furst⁷, Francis Guillemin⁸, Sarah Hewlett⁹, Amye L. Leong¹⁰, Lyn March¹¹, Thasia Woodworth¹², Gilles Boire¹³, Carol Hitchon¹⁴, Shahin Jamal¹⁵, Edward C. Keystone¹⁶, Janet E. Pope¹⁷, J Carter Thorne¹⁸, Diane Tin¹⁹, Susan J. Bartlett^20,21,22 and CATCH Investigators and OMERACT Flare Group, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁵Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁶The Parker instutute, RC, Copenhagen, Denmark, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Lorraine, Nancy, France, ⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹⁰Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹²Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ¹³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁷Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²⁰Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: A reference point for clinically important worsening (CIW) of RA disease activity requiring retreatment or escalation is needed for randomized trials of treatment withdrawal.…
Abstract Number: 2656 • 2015 ACR/ARHP Annual Meeting
Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Rieke Alten¹, Robert J. Holt², Jeffrey D. Kent³ and Frank Buttgereit⁴, ¹Charité Univ Medicine, Berlin, Germany, ²College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ³Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ⁴Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Patient reported outcomes such as morning stiffness are reported frequently in rheumatoid arthritis (RA) patients. But little has been reported about the presence and…
Abstract Number: 2657 • 2015 ACR/ARHP Annual Meeting
Influence of Anxiety and Depression on the Swollen to Tender Joint Count Ratio: In Pursuit of a Phenotype of RA Patients with Somatic Complaints in a U.S. Veteran Population
Iris Navarro-Millan¹, Archana Jain¹, Rebecca Belsom¹, Angelo L. Gaffo², Shuo Yang³, Ted R. Mikuls⁴ and Jeffrey R. Curtis⁵, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, Birmingham VA Medical Center, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The utilization of a swollen (SJC) to tender joint count (TJC) ratio (STR = (SJC/TJC)) has been proposed in the past to identify a…
Abstract Number: 2658 • 2015 ACR/ARHP Annual Meeting
Low Disease Activity Is Associated with Higher HDL and a Trend to Lower Insulin Resistance in Rheumatoid Arthritis Patients
Androniki Bili¹, Debra Webb¹, Cynthia Matzko², Andrea Berger³, Eric Newman⁴, Thomas Olenginski⁴, H. Lester Kirchner³, Jon Giles⁵ and Mary Chester M. Wasko⁶, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Rheumatology MC 13-41, Geisinger Medical Center, Danville, PA, ³Biostatistics, Geisinger Center for Health Research, Danville, PA, ⁴Department of Rheumatology, Geisinger Medical Center, Danville, PA, ⁵Columbia University Medical Center, New York, NY, ⁶West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA
Background/Purpose: Treat to target (T2T) trials in RA to date have focused on the effect of T2T on articular disease without directly addressing cardiovascular risk.…
Abstract Number: 2659 • 2015 ACR/ARHP Annual Meeting
Poor Correlation Between Vectra DA and DAS28 Scores in Patients with Rheumatoid Arthritis
Marcia S. Genta¹, Amnon Sonnenberg² and Robert M. Genta³, ¹Dallas Arthritis Center, Dallas, TX, ²Medicine - Gastroenterology, Portland VAMC - Oregon Health & Science University, Portland, OR, ³Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Vectra DA, a blood test that integrates the blood levels of 12 biomarkers into a single score (1-100), is claimed to provide an objective…
Abstract Number: 2660 • 2015 ACR/ARHP Annual Meeting
Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Nathalie Carrier¹, Anthony Marotta², Artur de Brum-Fernandes^3,4, Patrick Liang^3,4, Ariel Masetto^5,6, Yuan Gui², Jane Savill², Sara Michienzi², Henri Ménard⁷, Walter Maksymowych⁸ and Gilles Boire⁴, ¹Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The 14-3-3 family of conserved regulatory proteins consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ. These proteins exist as intracellular…
Abstract Number: 2661 • 2015 ACR/ARHP Annual Meeting
Assessing Information Needs for Chronic Disease Management in Rheumatoid Arthritis
Marylou Cardenas-Turanzas¹, Elsa Gonzalez², Maithili Shethia¹, Maria A. Lopez-Olivo³, Pratibha Nayak⁴ and Maria E. Suarez-Almazor³, ¹Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Higher Education Administration, Texas A&M University, Corpus Christi, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴National Institutes of Health, Atlanta, GA
Background/Purpose: Patients with chronic disease are increasingly using social networking to share experiences about their disease, and receive peer support. As part of an educational…
Abstract Number: 2662 • 2015 ACR/ARHP Annual Meeting
Validation of the Quickdash in the Assessment of Rheumatoid Arthritis Disease Activity
Cassandra Craig¹ and Matthew Carroll², ¹Internal Medicine, Keesler Medical Center, Keesler AFB, MS, ²Rheumatology, Keesler Medical Center, Keesler AFB, MS
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory arthritis associated with substantial morbidity and mortality. Measuring disease activity in RA is important as it…
Abstract Number: 2663 • 2015 ACR/ARHP Annual Meeting
Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice and Its Association with Disease Activity
E Alemao¹, KK Gandhi¹, C Iannaccone², M Frits², JS Coblyn², N Shadick² and Michael Weinblatt², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Testing for anti-citrullinated peptide antibodies (ACPA) is included in the 2010 ACR classification criteria for RA. ACPA concentration, beyond ACPA positivity, is indicative of…
Abstract Number: 2664 • 2015 ACR/ARHP Annual Meeting
Flares Occur Frequently in RA Patients Undergoing Arthroplasty
Susan M. Goodman¹, Rivka Friedlander², Caroline Figgie², Anh Hoang¹, Kathleen Andersen³, Alessandra B. Pernis⁴, Cristina T. Rozo⁵, Edward F. DiCarlo⁶, Mark P. Figgie⁷, Laura T. Donlin⁸ and VP Bykerk³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Research, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁵535 East 70th Street, Hospital for Special Surgery, New York, NY, ⁶Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁷Orthopaedics, Hospital for Special Surgery, New York, NY, ⁸Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: RA patients are at risk for disease worsening (flare) after joint surgery, as medication is withdrawn to mitigate infection risk. We aimed to describe…
Abstract Number: 2665 • 2015 ACR/ARHP Annual Meeting
Improved Flare/ Remission Pattern in Rheumatoid Arthritis over the Recent Decades
Elena Myasoedova¹, Sherine E. Gabriel², Eric L. Matteson³, John M. Davis III⁴ and Cynthia S. Crowson⁵, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Flare or episodic worsening of disease activity is an important aspect of the disease experience for patients with rheumatoid arthritis (RA), with significant impact…
Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…
Abstract Number: 2667 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment
Peter C. Taylor¹, Rieke Alten², Philippe Bertin³, Roberto Caporali⁴, Juan J Gomez-Reino⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Rheumatology, CHU Dupuytren, Limoges, France, ⁴University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁵Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Despite an increasing armamentarium of efficacious treatments for Rheumatoid Arthritis (RA), sustained remission remains an unrealistic expectation for many patients, with most experiencing ongoing…
Abstract Number: 2668 • 2015 ACR/ARHP Annual Meeting
Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate
T. W. J. Huizinga¹, SE Connolly², A Johnsen², J Zhu², Daniel E. Furst³, VP Bykerk⁴, Gerd Burmester⁵, BG Combe⁶, DA Wong², LA Trouw¹, René E. M. Toes¹ and Paul Emery⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Weill Cornell Medical College, New York, NY, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Montpellier University, Montpellier, France, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA, and the presence of the immunoglobulin M (IgM) isotype indicates an ongoing immune response involving…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].